News

In an interview with Targeted Oncology™, Guru Sonpavde, MD, discussed the safety and efficacy of fixed-dose durvalumab for UTC along with an overview of the ongoing CheckMate 274 trial, which evaluates nivolumab compared to placebo in this patient population. 

Phase 2 data show that tyrosine kinase inhibitors can be combined with chemotherapy to improve outcomes in patients with relapsed or refractory osteosarcoma.

In medullary thyroid cancer, older patients are more likely to have more aggressive disease and disease specific mortality.

In an interview with Targeted Oncology, Melissa K. Frey, MD, discussed findings from implementing web-based health information collection of family history in patients with gynecologic cancers.

The BELINDA clinical trial results show that tisagenlecleucel did not outperform standard of care in aggressive B-cell non-Hodgkin lymphoma.

While brain tumor rates are declining, 5-year survival remains low at 36%. Incidence rates of adult brain tumors are decreasing; however, 5-year survival rates remain low.

Haris Ali, MD, a hematology oncologist at the City of Hope Comprehensive Cancer Center, discusses common myeloproliferative neoplasms driver mutations. 

Enrollment in the phase 2b PARADIGME trial of 177Lu lilotomab satetraxetan (Betalutin) in patients with follicular lymphoma has continued despite the surge of the COVID-19 Delta variant.

In the wake of immunotherapy combinations becoming available in breast cancer, including triple-negative breast cancer, the Society for Immunotherapy of Cancer has published clinical practice guidelines for physicians treating in this setting.

The first patient has been dosed in a trial of FHD-609, a selective protein degrader of bromodomain-containing protein 9, for the treatment of synovial sarcoma.

The National Comprehensive Cancer Network has issued support for mandatory COVID-19 vaccinations for health care workers as the FDA issues full approval to the Pfizer-BioNTech COVID-19 vaccine.

The FDA has accepted the supplemental biologics license application for abatacept and granted it priority review for the prevention of moderate to severe acute graft versus host disease in patients 6 years of age and older receiving unrelated donor hematopoietic stem cell transplantation.

Peter Riedell, MD, an assistant professor of medicine at University of Chicago Medicine, discusses outcomes for mantle cell lymphoma patients and the impact of the timing of relapse on overall survival after autologous stem cell transplantation.

Bishoy M. Faltas, MD, Fellow, Hematology/Oncology, Weill Cornell Medical College, discusses genomic testing in urothelial cancer.

Cora N. Sternberg, MD, discusses the case of a 66-year-old woman with bladder cancer.

In an interview with Targeted Oncology™, Stephanie L. Wethington, MD, MSc, discussed the modern treatment of high-grade serous ovarian cancer and the study of olaparib plus ceralasertib as a strategy for overcoming resistance to PARP inhibition.

Oncologists treating patients with HER2-expressing solid tumors can now refer patients for enrollment in a phase 2 trial of the novel drug A166, that has shown high potency in these tumors.

The off-the-shelf iPSC-derived NK Cell agents, FT516 AND FT596, which are being developed for the treatment of B-cell malignancies, show promise and early clinical benefit.

The FDA has granted approval to nivolumab as an adjuvant treatment of patients with urothelial carcinoma who are at high risk of recurrence after undergoing radical resection, regardless of prior neoadjuvant chemotherapy, nodal involvement or PD-L1 status.

In an interview with Targeted Oncology™, Erica Stringer-Reasor, MD, discusses the study in more detail and how this newly approved triplet combination may improve survival for patients living with HER2-positive breast cancer with central nervous system metastases.

In an interview with Targeted Oncology™, Isabelle Ray-Coquard, MD, PhD, discussed the NEOPEMBROV study in greater detail and the benefits of adding pembrolizumab to perioperative treatment for serous carcinoma deemed non-optimally resectable.

Treatment with amivantamab-vmjw in the phase 1 CHRYSALIS study has released anti-tumor activity in patients with non-small cell lung cancer harboring MET exon 14 skipping mutations treated with the agent.

Jorge Nieva, MD, discusses the results of the Impower010 study, which evaluated the efficacy of the checkpoint inhibitor atezolizumab after chemotherapy for lung cancer compared to best supportive care. 

The FDA has approved the Ventana MMR RxDx Panel, a companion diagnostic test to determine which patients with DNA mismatch repair deficiency are likely to benefit from the anti-PD-1 monotherapy dostarlimab-gxly.

The FDA has granted fast track designation to the highly selective inhibitor of casein kinase 2 inhibitor, silmitasertib for the treatment of patients with recurrent sonic hedgehog-driven medulloblastoma.

Three centers in the United States are recruiting patients with indolent non-Hodgkin lymphoma to receive the investigational selective PI3Kδ inhibitor zandelisib in combination with rituximab in a phase 3 clinical trial setting. The study aims to determine the efficacy and safety of zandelisib in combination with rituximab compared with standard immunochemotherapy.

Thomas Marron, MD, PhD an assistant professor of hematology and medical oncology at Mount Sinai Hospital, discusses the study design and key goals of adding perioperative cemiplimab, an anti-PD-1 antibody, to surgical resection for hepatocellular carcinoma.

The FDA has granted a fast track designation to the folate receptor alpha-targeting antibody-drug conjugate, STRO-002, for the treatment of patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received 1 to 3 prior lines of systemic therapy.

The Oncoguard Liver liquid biopsy test has demonstrated a high sensitivity and specificy for the detection of hepatocellular carcinoma (HCC), including in patients with early-stage HCC.

The FDA granted an accelerated approval to dostarlimab-gxly (Jemperli), a programmed cell death receptor-1 blocking antibody, for the treatment of adult patients with mismatch repair-deficient recurrent or advanced solid tumors that have progressed on or following prior treatment and who have no satisfactory alternative treatment options.